Skip to content
Back to meeting Original
Dr. Antonio Calles 🫁🚭· @Tony_Calles · X·· 5 hours agoScore70

rezetecan

Body · original

HERON-Lung01: Ruzaltatug rezetecan (SHR-A2009), antiHER3 ADC, showed increased efficacy in terms of ORR and PFS, but OS not mature yet compared to pt-based chemotherapy. Significant toxicities. Not a SoC yet to me. #ESMO26 #LCSM

27 views · 1 like · 0 reposts · 0 replies

Conference abstracts
LBA13matched by Proffered paper 1: Breast cancer, early and advanced stage

Trastuzumab rezetecan (SHR-A1811) in HER2-low advanced breast cancer (BC): A randomized, phase 3 study (HORIZON-Breast06)

https://esmocongress.esmo.org

Source: Dr. Antonio Calles 🫁🚭 · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.